Differences in trans-Tasman patent law: extension of term for pharmaceuticals

This is the latest in a series of articles intended to highlight some of the major differences between the patent laws of Australia and New Zealand. Whereas patentees are typically encouraged to view Australia and New Zealand as a common market, the reality is that this impression may not be 100% accurate. As may be

A Kiwi-sized spanner in the works of the TPP?

We have previously reported on progress toward the Trans-Pacific Partnership (TPP) – a Free Trade Agreement (FTA) presently under negotiation by Australia, Brunei Darussalam, Chile, Canada, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, and Vietnam. Recently, the negotiating parties set themselves a goal of finalising the agreement by October 2013. The TPP will

The TPP, IP and the Australasian healthcare industry – what’s at stake?

The Trans-Pacific Partnership (TPP) is a Free Trade Agreement (FTA) presently under negotiation by Australia, Brunei Darussalam, Chile, Canada, Malaysia, Mexico, New Zealand, Peru, Singapore, the United States, and Vietnam. Its earliest origins date back to 2005 – and in December 2012, the fifteenth round of negotiations took place in Auckland, New Zealand. Recently, the

Progress toward a unitary patent examination for Australia and New Zealand

Back in February 2011, we reported on moves toward a unitary patent examination process for Australia and New Zealand. This was part of the Single Economic Market (SEM) reforms, as agreed between the Australian and New Zealand Governments in late 2009. We noted that whilst such unitary examination is believed to be a “world first”,

Page 2 of 212